Page last updated: 2024-11-04

rolipram and Colonic Neoplasms

rolipram has been researched along with Colonic Neoplasms in 2 studies

Colonic Neoplasms: Tumors or cancer of the COLON.

Research Excerpts

ExcerptRelevanceReference
"One of the major problems in treating colon cancer is chemoresistance to cytotoxic chemotherapeutic agents."1.34Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. ( Baillie, GS; Brunton, VG; Frame, MC; Houslay, MD; Leslie, NR; McEwan, DG, 2007)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Miklos, W1
Heffeter, P1
Pirker, C1
Hager, S1
Kowol, CR1
van Schoonhoven, S1
Stojanovic, M1
Keppler, BK1
Berger, W1
McEwan, DG1
Brunton, VG1
Baillie, GS1
Leslie, NR1
Houslay, MD1
Frame, MC1

Other Studies

2 other studies available for rolipram and Colonic Neoplasms

ArticleYear
Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Res

2016
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
    Cancer research, 2007, Jun-01, Volume: 67, Issue:11

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell

2007